Navigation Links
US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
Date:7/17/2013

London, UK (PRWEB) July 17, 2013

Dermatophytic onychomycosis (DO) is one of the most widespread fungal nail infections. It is not considered to be a life-threatening disease, but it can cause considerable pain and discomfort. At present, DO therapies consist of generics which are quite effective but are not as safe as their brand-name counterparts.

New topical DO therapies are predicted to be introduced in the offing, and they are likely to scale up the total drug treatment rates in the US owing to increasing physicians’ awareness of safer and more effective treatment options. Meanwhile, given their advantages such as a shorter duration of treatment, generic therapies represent a challenge to the development of the innovative therapies.

Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 146
Price:    US$ 4,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/dermatophytic-onychomycosis-do-us-drug-forecast-n-market-analysis-to-2022.html

The report provides in-depth insights into the US DO market. It uncovers vital general information on DO including its epidemiology, key symptoms and disease treatment; and also discloses historical and present data on the DO market revenues, annual therapy costs, treatment usage patterns, etc. The study contains a comprehensive pipeline analysis, evaluates the competitive environment, and presents details on the top companies operating in the market. The report examines major market drivers and restraints, outlines the market opportunities and challenges, characterizes prevailing development trends, and moreover, sheds light on the possible path of the market development through 2022.

Report Scope:

  •     Comprehensive overview of DO (epidemiology, general symptoms, disease treatment recommendations, etc.).
  •     All-round analysis of the US DO market.
  •     Historical and present data on the market performance.
  •     Description of the competitive scenario.
  •     Vital information on the major market opportunities.
  •     Clinical pipeline assessment.
  •     Profiles of the leading market players.
  •     Discussion of the important industry issues.
  •     Examination of the factors driving and restraining the market development.
  •     Detailed future market forecast up to 2022.

More research studies by the publisher can be found at GlobalData page.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937702.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Francisco, CA (PRWEB) , ... February 20, 2017 ... ... reduce infections in patients with catheters associated with peritoneal dialysis, announced today that ... light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include ... weighing equipment with the goal of expanding the reach of its quality and ... Starter water analysis meters were introduced into the market in 2014. , The ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... flying hobbyists, and DJI, the world’s leading maker of unmanned aircraft systems (UAS), ... public safety officers to use drones effectively, and support educational outreach efforts. , ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):